LL-37safety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for LL-37 as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. LL-37 is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

LL-37 presents a substantially more complex safety profile than most research peptides, primarily because it is a potent biological mediator with established pathogenic roles at elevated concentrations. At the concentrations present in normal human tissues (estimated 1–5 µg/mL in sweat and wound fluid, lower in plasma), LL-37 is well tolerated and is essential for mucosal and cutaneous defence. The therapeutic index of exogenously administered LL-37 is less well characterised. In animal studies, subcutaneous and topical delivery has generally been tolerated, but systemic intravenous administration at high doses has been associated with cardiovascular effects attributable to the peptide's membrane-active properties on mammalian cell membranes — selectivity for prokaryotic versus eukaryotic membranes is not absolute. The inflammatory amplification capacity of LL-37 is the most practically relevant safety consideration in research contexts. In individuals with predisposing conditions (atopic diathesis, psoriasis, rosacea), supraphysiological LL-37 concentrations — even topically applied — could theoretically exacerbate skin disease by activating the TLR7/9-pDC-IFN-α axis. This has not been characterised systematically in controlled research, but the mechanistic basis is well established. A significant practical problem in LL-37 research is adsorption to plastic surfaces. LL-37 is highly cationic and binds avidly to standard polystyrene and polypropylene labware, leading to substantial and unpredictable losses of effective concentration. Studies that do not account for adsorption losses may report effective concentrations that are considerably lower than nominal. Low-binding tubes and plates, and addition of carrier protein (BSA at 0.1–0.01%) in non-cellular assays, are recommended in the research literature. Serum and tissue proteins bind LL-37 extensively. Alpha-2-macroglobulin, LDL, and glycosaminoglycans (notably heparan sulphate) all sequester LL-37 and reduce its free concentration, further complicating dose interpretation in cell-culture media containing foetal bovine serum. This protein-binding effect also means plasma half-life measured in vivo may not reflect biologically active concentration at tissue sites.

UK regulatory status

LL-37 is not authorised as a medicine by the UK Medicines and Healthcare products Regulatory Agency (MHRA). There is no marketing-authorisation application for LL-37 on record in the UK or European Medicines Agency databases as a standalone pharmaceutical. LL-37 is not included on the World Anti-Doping Agency (WADA) Prohibited List as of the 2025 iteration. It does not have anabolic, lipolytic, or growth-promoting properties that would place it within the classes of peptides most commonly targeted by WADA (S0, S1, S2). Athletes and researchers in competitive-sport contexts should nevertheless verify the current list, as WADA periodically updates categories. In the United Kingdom, possession of LL-37 for genuine in-vitro laboratory research is unrestricted. It is not a scheduled substance under the Misuse of Drugs Act 1971. Supply for human therapeutic administration or promotion of such use would require MHRA authorisation. No enforcement actions against LL-37 specifically have been publicly reported by the MHRA.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. LL-37 is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full LL-37 research context including mechanism, study citations, and references, see the main LL-37 research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.